Poseida Therapeutics (PSTX) Competitors $9.39 -0.03 (-0.32%) (As of 11:46 AM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends PSTX vs. VRNA, BHVN, PTCT, RYTM, MLTX, JANX, MRUS, XENE, ZLAB, and MORShould you be buying Poseida Therapeutics stock or one of its competitors? The main competitors of Poseida Therapeutics include Verona Pharma (VRNA), Biohaven (BHVN), PTC Therapeutics (PTCT), Rhythm Pharmaceuticals (RYTM), MoonLake Immunotherapeutics (MLTX), Janux Therapeutics (JANX), Merus (MRUS), Xenon Pharmaceuticals (XENE), Zai Lab (ZLAB), and MorphoSys (MOR). These companies are all part of the "pharmaceutical products" industry. Poseida Therapeutics vs. Verona Pharma Biohaven PTC Therapeutics Rhythm Pharmaceuticals MoonLake Immunotherapeutics Janux Therapeutics Merus Xenon Pharmaceuticals Zai Lab MorphoSys Poseida Therapeutics (NASDAQ:PSTX) and Verona Pharma (NASDAQ:VRNA) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation, analyst recommendations, community ranking and media sentiment. Do analysts recommend PSTX or VRNA? Poseida Therapeutics presently has a consensus target price of $9.50, indicating a potential upside of 0.85%. Verona Pharma has a consensus target price of $43.83, indicating a potential downside of 5.10%. Given Poseida Therapeutics' higher possible upside, equities research analysts plainly believe Poseida Therapeutics is more favorable than Verona Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Poseida Therapeutics 0 Sell rating(s) 5 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Verona Pharma 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community favor PSTX or VRNA? Verona Pharma received 283 more outperform votes than Poseida Therapeutics when rated by MarketBeat users. Likewise, 80.55% of users gave Verona Pharma an outperform vote while only 63.49% of users gave Poseida Therapeutics an outperform vote. CompanyUnderperformOutperformPoseida TherapeuticsOutperform Votes4063.49% Underperform Votes2336.51% Verona PharmaOutperform Votes32380.55% Underperform Votes7819.45% Does the media refer more to PSTX or VRNA? In the previous week, Verona Pharma had 6 more articles in the media than Poseida Therapeutics. MarketBeat recorded 6 mentions for Verona Pharma and 0 mentions for Poseida Therapeutics. Verona Pharma's average media sentiment score of 0.33 beat Poseida Therapeutics' score of 0.00 indicating that Verona Pharma is being referred to more favorably in the news media. Company Overall Sentiment Poseida Therapeutics Neutral Verona Pharma Neutral Do institutionals & insiders have more ownership in PSTX or VRNA? 46.9% of Poseida Therapeutics shares are held by institutional investors. Comparatively, 85.9% of Verona Pharma shares are held by institutional investors. 2.9% of Poseida Therapeutics shares are held by company insiders. Comparatively, 4.8% of Verona Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has more volatility and risk, PSTX or VRNA? Poseida Therapeutics has a beta of 1.64, indicating that its share price is 64% more volatile than the S&P 500. Comparatively, Verona Pharma has a beta of 0.46, indicating that its share price is 54% less volatile than the S&P 500. Is PSTX or VRNA more profitable? Verona Pharma has a net margin of 0.00% compared to Poseida Therapeutics' net margin of -40.28%. Poseida Therapeutics' return on equity of -72.26% beat Verona Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Poseida Therapeutics-40.28% -72.26% -21.53% Verona Pharma N/A -79.54%-43.49% Which has better earnings and valuation, PSTX or VRNA? Verona Pharma has lower revenue, but higher earnings than Poseida Therapeutics. Verona Pharma is trading at a lower price-to-earnings ratio than Poseida Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPoseida Therapeutics$150.86M6.11-$123.43M-$0.63-14.95Verona Pharma$5.62M660.65-$54.37M-$1.92-24.06 SummaryVerona Pharma beats Poseida Therapeutics on 11 of the 18 factors compared between the two stocks. Ad Porter & CompanyViral Trump video releasedPorter Stansberry’s latest video is going viral… In this bombshell exposé, famed economist Porter Stansberry reveals what happened during his trip to Mar-a-Lago, his meeting with Donald Trump, and the 10 urgent money moves to make before Jan 20 inauguration. Your link to watch Trump’s Secret Stocks is here. Get Poseida Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PSTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PSTX vs. The Competition Export to ExcelMetricPoseida TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$921.03M$2.97B$5.21B$9.13BDividend YieldN/A1.89%4.96%4.20%P/E Ratio-14.9546.4687.5417.22Price / Sales6.11411.651,119.09124.54Price / CashN/A174.7643.2737.85Price / Book8.724.024.855.00Net Income-$123.43M-$42.00M$120.16M$225.21M7 Day Performance-0.63%2.49%2.05%3.81%1 Month Performance1.18%-3.21%15.98%2.69%1 Year Performance180.36%14.48%28.82%18.12% Poseida Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PSTXPoseida Therapeutics3.3086 of 5 stars$9.39-0.3%$9.50+1.2%+180.4%$918.10M$150.86M-14.90260VRNAVerona Pharma0.8671 of 5 stars$45.68+8.7%$43.83-4.0%+132.3%$3.67B$5.62M-23.7930BHVNBiohaven3.798 of 5 stars$35.80-1.3%$63.00+76.0%-14.3%$3.62B$462.51M-3.83239PTCTPTC Therapeutics3.7574 of 5 stars$45.28-2.1%$54.08+19.4%+64.1%$3.49B$900.66M-7.621,410RYTMRhythm Pharmaceuticals3.9798 of 5 stars$56.19+0.1%$66.90+19.1%+20.9%$3.45B$112.53M-12.98140MLTXMoonLake Immunotherapeutics1.2544 of 5 stars$52.41+0.5%$81.43+55.4%-8.3%$3.35BN/A-40.632JANXJanux Therapeutics3.6417 of 5 stars$56.30-0.9%$89.90+59.7%+404.2%$2.95B$13.05M-48.1230Analyst UpgradeInsider TradeShort Interest ↑MRUSMerus2.5138 of 5 stars$42.65+1.9%$85.64+100.8%+53.0%$2.92B$43.95M-10.8037Positive NewsXENEXenon Pharmaceuticals2.5035 of 5 stars$38.05-1.5%$56.00+47.2%-15.7%$2.90B$9.43M-13.49251ZLABZai Lab2.084 of 5 stars$26.59-0.5%$55.00+106.8%-2.6%$2.89B$355.75M-9.602,175MORMorphoSys0.0687 of 5 stars$18.96flat$14.33-24.4%N/A$2.86B$238.28M-5.45730 Related Companies and Tools Related Companies VRNA Competitors BHVN Competitors PTCT Competitors RYTM Competitors MLTX Competitors JANX Competitors MRUS Competitors XENE Competitors ZLAB Competitors MOR Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PSTX) was last updated on 12/30/2024 by MarketBeat.com Staff From Our PartnersURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored3 CENT Crypto to Explode December 16th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredViral Trump video releasedPorter Stansberry’s latest video is going viral… In this bombshell exposé, famed economist Porter Stansberr...Porter & Company | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | SponsoredWhy Buffett, Griffin and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Poseida Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Poseida Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
